Dutasteride

Dutasteride shows greater efficacy than finasteride for treating androgenetic alopecia, while maintaining a comparable safety profile.

A consensus of experts identified seven recommended interventions for AGA, including oral and topical finasteride, dutasteride, and minoxidil, while identifying 17 interventions that are not recommended.

The review discusses the potential of topical dutasteride and nanocarrier delivery systems to provide an effective alternative to oral treatments while minimizing systemic absorption.

Dutasteride (0.5 mg and 2.5 mg) is significantly more effective than finasteride (1 mg) at increasing hair counts in both males and females with AGA.

Various over-the-counter, prescription, and procedural treatments successfully promote hair growth, suggesting that a multifaceted, individualized approach is most effective.

Oral dutasteride demonstrates better efficacy than finasteride for AGA with similar tolerability, while topical delivery methods like microneedling or mesotherapy may reduce systemic adverse events.

Low-dose oral minoxidil has demonstrated a favorable efficacy and safety profile for both male and female androgenetic alopecia.

Various treatments including 5-alpha reductase inhibitors, oral minoxidil, and PRP show efficacy, though evidence for some newer or non-pharmacological methods remains limited.

Dutasteride 0.5 mg/d is ranked as the most effective treatment, followed by higher doses of finasteride and minoxidil.

Finasteride may promote hair regrowth in women with FPHL, but its use is limited by potential teratogenic risks; topical finasteride and dutasteride are explored as alternative strategies.

The review does not report efficacy outcomes for hair growth; it focuses on potential adverse metabolic and systemic effects of long-term 5α-reductase inhibition.

The review concludes that finasteride and dutasteride can cause persistent sexual, neurological, and physical side effects in a subset of men, constituting post-finasteride syndrome, for which no evidence-based treatments currently exist.

Finasteride and minoxidil can halt disease progression but only yield partial hair regrowth; early initiation improves outcomes, and PRP may be considered for patients unresponsive to medical therapy.

Low-level laser therapy showed superior relative effects for hair regrowth compared to other non-surgical treatments, while PRP, finasteride, minoxidil, and dutasteride demonstrated approximately equivalent mean changes in hair count.

The meta-analysis found that treatment with finasteride or dutasteride for male androgenetic alopecia is associated with an increased risk of sexual dysfunction, with finasteride showing a statistically significant 66% higher risk compared to placebo, while dutasteride showed a non-significant 37% increase.

Dutasteride is found to be more effective than finasteride for treating androgenetic alopecia with comparable adverse effects.

First-line therapies recommended include oral finasteride 1 mg daily, oral dutasteride 0.5 mg daily, topical 5% minoxidil twice daily for MPHL and topical 1% minoxidil twice daily for FPHL, along with low-level laser therapy and hair transplantation.

The review highlights several emerging therapies, including novel excipients for oral minoxidil, dutasteride, and finasteride; topical prostaglandin modulators; low-level laser therapy; Wnt pathway activators and stem cell treatments for androgenetic alopecia; JAK inhibitors for alopecia areata; antiandrogens and pioglitazone for frontal fibrosing alopecia; and robotic-assisted follicular unit extraction for hair transplantation.

Topical minoxidil shows moderate efficacy in increasing hair regrowth and hair count in women with FPHL, with no clear advantage of 5% over 2% concentration; oral finasteride 1 mg is not more effective than placebo; low-level laser therapy may increase hair count but clinical relevance is uncertain.

Current treatments (minoxidil, finasteride) offer limited and non-permanent benefits; hair transplantation is the only permanent option, while other off-label agents and laser therapies are commonly used despite modest or inconsistent efficacy.

Treatments such as topical minoxidil and 5‑alpha reductase inhibitors (finasteride, dutasteride) can slow hair loss progression and promote regrowth, but continuous use is required to maintain benefit.

Dutasteride 0.5 mg significantly increased hair count and width and improved hair growth compared to both finasteride 1 mg and placebo.

Minoxidil and finasteride remain the standard treatments, with hair transplantation as a surgical option; dutasteride, ketoconazole, and prostaglandin analogues (latanoprost, bimatoprost) are used or under investigation, and low-level laser therapy is gaining popularity, though robust clinical trial data proving hair growth efficacy are limited.

Dutasteride increased hair count in a dose-dependent manner; the 2.5 mg dose produced greater hair growth than finasteride 5 mg at both 12 and 24 weeks.